$911.91 Million in Sales Expected for MEDNAX Inc (MD) This Quarter

Brokerages expect MEDNAX Inc (NYSE:MD) to post $911.91 million in sales for the current quarter, according to Zacks Investment Research. Nine analysts have made estimates for MEDNAX’s earnings. The highest sales estimate is $926.60 million and the lowest is $897.74 million. MEDNAX reported sales of $842.94 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 8.2%. The company is expected to report its next earnings results on Friday, July 27th.

According to Zacks, analysts expect that MEDNAX will report full-year sales of $3.71 billion for the current fiscal year, with estimates ranging from $3.66 billion to $3.75 billion. For the next financial year, analysts forecast that the firm will post sales of $3.95 billion per share, with estimates ranging from $3.87 billion to $4.06 billion. Zacks’ sales averages are a mean average based on a survey of research firms that follow MEDNAX.

MEDNAX (NYSE:MD) last posted its quarterly earnings data on Monday, April 30th. The company reported $0.89 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.07. The company had revenue of $901.90 million during the quarter, compared to analyst estimates of $903.75 million. MEDNAX had a net margin of 9.34% and a return on equity of 10.13%. The company’s revenue was up 7.9% on a year-over-year basis. During the same quarter last year, the business posted $0.75 earnings per share.

A number of analysts recently weighed in on the stock. TheStreet raised shares of MEDNAX from a “c+” rating to a “b” rating in a report on Monday, March 12th. ValuEngine lowered shares of MEDNAX from a “sell” rating to a “strong sell” rating in a report on Wednesday, May 2nd. Stephens set a $62.00 target price on shares of MEDNAX and gave the stock a “buy” rating in a report on Thursday, February 8th. Zacks Investment Research raised shares of MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a report on Tuesday, January 23rd. Finally, JPMorgan Chase lifted their target price on shares of MEDNAX from $46.00 to $55.00 and gave the stock a “neutral” rating in a report on Monday, February 12th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $55.92.

Shares of MEDNAX opened at $47.02 on Monday, Marketbeat reports. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.74 and a quick ratio of 1.74. The company has a market capitalization of $4.44 billion, a P/E ratio of 14.93, a P/E/G ratio of 1.19 and a beta of 0.26. MEDNAX has a fifty-two week low of $40.56 and a fifty-two week high of $63.04.

In other news, insider John C. Pepia sold 3,000 shares of MEDNAX stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $58.35, for a total transaction of $175,050.00. Following the transaction, the insider now directly owns 39,716 shares of the company’s stock, valued at $2,317,428.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sandy Spring Bank bought a new position in shares of MEDNAX during the first quarter worth $176,000. Blair William & Co. IL bought a new position in shares of MEDNAX during the first quarter worth $211,000. Delta Capital Management LLC bought a new position in shares of MEDNAX during the fourth quarter worth $227,000. Brown Advisory Inc. bought a new position in shares of MEDNAX during the fourth quarter worth $231,000. Finally, Shelton Capital Management bought a new position in shares of MEDNAX during the fourth quarter worth $245,000. 99.37% of the stock is currently owned by institutional investors.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply